Vietnam Tariff Intelligence

# HS 3004.90.64 detail

| | |
|---|---|
| **HS code** | 3004.90.64 |
| **Description** | Medicaments (excluding goods of heading 30.02, 30.05 or 30.06) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packings for retail sale / - Other: / - - Antimalarials: / - - - Containing artemisinin other than of subheading 3004.60.10 |
| **Unit** | kg/chiếc |
| **Generated** | 05/11/2026 08:58:25 |
| **Data version** | 2026.04.05 – BIEU THUE XNK 2026.04.05.xlsx |
| **Verification status** | Tariff data checked against the source file; advice/mappings are indicative; FTA eligibility not verified. |
| **Link** | https://vietnamtariff.com/hs-code/30049064/ |

## Taxes applicable in 2026

| Tariff scheme | Source value | Rate | Legal basis | effective | Source |
|---|---|---|---|---|---|
| Ordinary import duty | 7.5 | 7.5% | 15/2023/QĐ-TTg | 2023-07-15 | BT2026!K4636 |
| Preferential (MFN) | 5 | 5% | 26/2023/NĐ-CP | 2023-07-15 | BT2026!N4636 |
| VAT | 5/8/10 | 5 / 8 / 10 (several rates) | 181/2025/NĐ-CP | 2025-07-01 | BT2026!Q4636 |
| Excise tax | | No data | | | |
| Environmental tax | | No data | | | |
| Export duty | | No data | | | |
| CPTPP export rate | | No data | | | |
| EVFTA export rate | | No data | | | |
| UKVFTA export rate | | No data | | | |

## Special preferential (FTA) rates – 2026

| FTA | Source value | Rate | Data basis | Period | Proof of origin | Legal basis | Status |
|---|---|---|---|---|---|---|---|

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AANZFTA | 0 | 0% | Consolidated BT2026 | 2022 - 2027 (một mức cho cả giai đoạn) | AANZ | 121/2022/NĐ-CP | Ad valorem |
| ACFTA | 0 | 0% | Consolidated BT2026 | 2022 - 2027 (một mức cho cả giai đoạn) | E | 118/2022/NĐ-CP | Ad valorem |
| AHKFTA | 0 | 0% | Consolidated BT2026 | 2026 | AHK | 123/2022/NĐ-CP | Ad valorem |
| AJCEP | 0 | 0% | Consolidated BT2026 | 01/4/2026 - 31/3/2027 | AJ | 120/2022/NĐ-CP | Ad valorem |
| AKFTA | 0(-LA, MY) | 0% (except LA, MY) | Consolidated BT2026 | 2022 - 2027 (một mức cho cả giai đoạn) | AK | 119/2022/NĐ-CP | Ad valorem |
| ATIGA | 0 | 0% | Consolidated BT2026 | 2026 | D | 126/2022/NĐ-CP | Ad valorem |
| CPTPP | 0 | 0% | Consolidated BT2026 | (VI) | CPTPP | 115/2022/NĐ-CP | Ad valorem |
| VCFTA | 0 | 0% | Consolidated BT2026 | 2026 | VC | 112/2022/NĐ-CP | Ad valorem |
| VJEPA | 0 | 0% | Consolidated BT2026 | 01/4/2026 - 31/3/2027 | JV · Form VJ | 124/2022/NĐ-CP | Ad valorem |
| VKFTA | 0 | 0% | Consolidated BT2026 | 2026 | VK | 125/2022/NĐ-CP | Ad valorem |
| VN-EAEU | 0 | 0% | Consolidated BT2026 | 2026 | EAV | 113/2022/NĐ-CP | Ad valorem |
| VN-LAO | 0 | 0% | Consolidated BT2026 | | S | 206/2025/NĐ-CP | Ad valorem |
| EVFTA | 0,6 | 0.6% | Consolidated BT2026 | 2026 | EUR.1 | 116/2022/NĐ-CP | Ad valorem |
| UKVFTA | 0,6 | 0.6% | Consolidated BT2026 | 2026 | EUR.1 | 117/2022/NĐ-CP | Ad valorem |
| RCEP (Annex A) | 2,5 | 2.5% | Consolidated BT2026 | 2026 | RCEP Form / Declaration of origin | 129/2022/NĐ-CP | Ad valorem |
| RCEP (Annex B) | 2,5 | 2.5% | Consolidated BT2026 | 2026 | RCEP Form / Declaration of origin | 129/2022/NĐ-CP | Ad valorem |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| RCEP (Annex C) | 2,5 | 2.5% | Consolidated BT2026 | 2026 | RCEP Form / Declaration of origin | 129/2022/NĐ-CP | Ad valorem |
| RCEP (Annex E) | 2,5 | 2.5% | Consolidated BT2026 | 2026 | RCEP Form / Declaration of origin | 129/2022/NĐ-CP | Ad valorem |
| RCEP (Annex F) | 2,5 | 2.5% | Consolidated BT2026 | 2026 | RCEP Form / Declaration of origin | 129/2022/NĐ-CP | Ad valorem |
| RCEP (Annex D) | 2,7 | 2.7% | Consolidated BT2026 | 2026 | RCEP Form / Declaration of origin | 129/2022/NĐ-CP | Ad valorem |
| VIFTA | 2.9 | 2.9% | Consolidated BT2026 | 2026 | Form VI (verify) | 131/2024/NĐ-CP | Ad valorem |
| AIFTA | 5 | 5% | Consolidated BT2026 | 01/01/2026 - 31/12/2026 | AI | 122/2022/NĐ-CP | Ad valorem |
| VN-CAM | | No data | No data | | S | 56/2026/NĐ-CP | No data |
| VNCU | | No data | No data | | VNCB · Form VC (Cuba) | 114/2022/NĐ-CP | No data |

## Rate history / phase-down by year

| FTA | Period | Year | Source value | Source |
|---|---|---|---|---|
| ACFTA | 2022 - 2027 (một mức cho cả giai đoạn) | | 0 | AC!E4558 |
| ATIGA | 2022 | 2022 | 0 | AT!E4519 |
| ATIGA | 2023 | 2023 | 0 | AT!F4519 |
| ATIGA | 2024 | 2024 | 0 | AT!G4519 |
| ATIGA | 2025 | 2025 | 0 | AT!H4519 |
| ATIGA | 2026 | 2026 | 0 | AT!I4519 |
| ATIGA | 2027 | 2027 | 0 | AT!J4519 |
| AJCEP | 30/12/2022 - 31/3/2023 | 2022 | 0 | AJ!E4557 |
| AJCEP | 01/4/2023 - 31/3/2024 | 2023 | 0 | AJ!F4557 |
| AJCEP | 01/4/2024 - 31/3/2025 | 2024 | 0 | AJ!G4557 |
| AJCEP | 01/4/2025 - 31/3/2026 | 2025 | 0 | AJ!H4557 |

| FTA | Period | Year | Source value | Source |
|---|---|---|---|---|
| AJCEP | 01/4/2026 - 31/3/2027 | 2026 | 0 | AJ!I4557 |
| AJCEP | 01/4/2027 - 31/3/2028 | 2027 | 0 | AJ!J4557 |
| VJEPA | 30/12/2022 - 31/3/2023 | 2022 | 0 | VJ!E4561 |
| VJEPA | 01/4/2023 - 31/3/2024 | 2023 | 0 | VJ!F4561 |
| VJEPA | 01/4/2024 - 31/3/2025 | 2024 | 0 | VJ!G4561 |
| VJEPA | 01/4/2025 - 31/3/2026 | 2025 | 0 | VJ!H4561 |
| VJEPA | 01/4/2026 - 31/3/2027 | 2026 | 0 | VJ!I4561 |
| VJEPA | 01/4/2027 - 31/3/2028 | 2027 | 0 | VJ!J4561 |
| AKFTA | 2022 - 2027 (một mức cho cả giai đoạn) | | 0 | AK!F4561 |
| AANZFTA | 2022 - 2027 (một mức cho cả giai đoạn) | | 0 | AANZ!H4525 |
| AIFTA | 30/12/2022 | 2022 | 5 | AI!F4521 |
| AIFTA | 31/12/2022 - 30/12/2023 | 2023 | 5 | AI!G4521 |
| AIFTA | 31/12/2023 - 30/12/2024 | 2024 | 5 | AI!H4521 |
| AIFTA | 31/12/2024 - 31/12/2025 | 2025 | 5 | AI!I4521 |
| AIFTA | 01/01/2026 - 31/12/2026 | 2026 | 5 | AI!J4521 |
| AIFTA | 01/01/2027 - 31/12/2027 | 2027 | 5 | AI!K4521 |
| VKFTA | 2022 | 2022 | 0 | VK!E4521 |
| VKFTA | 2023 | 2023 | 0 | VK!F4521 |
| VKFTA | 2024 | 2024 | 0 | VK!G4521 |
| VKFTA | 2025 | 2025 | 0 | VK!H4521 |
| VKFTA | 2026 | 2026 | 0 | VK!I4521 |
| VKFTA | 2027 | 2027 | 0 | VK!J4521 |
| VCFTA | 2022 | 2022 | 5 | VC!D4568 |
| VCFTA | 2023 | 2023 | 5 | VC!E4568 |
| VCFTA | 2024 | 2024 | 0 | VC!F4568 |
| VCFTA | 2025 | 2025 | 0 | VC!G4568 |

| FTA | Period | Year | Source value | Source |
|---|---|---|---|---|
| VCFTA | 2026 | 2026 | 0 | VC!H4568 |
| VCFTA | 2027 | 2027 | 0 | VC!I4568 |
| VN-EAEU | 2022 | 2022 | 0 | EAV!D4565 |
| VN-EAEU | 2023 | 2023 | 0 | EAV!E4565 |
| VN-EAEU | 2024 | 2024 | 0 | EAV!F4565 |
| VN-EAEU | 2025 | 2025 | 0 | EAV!G4565 |
| VN-EAEU | 2026 | 2026 | 0 | EAV!H4565 |
| VN-EAEU | 2027 | 2027 | 0 | EAV!I4565 |
| AHKFTA | 2022 | 2022 | 0 | AKH!D4573 |
| AHKFTA | 2023 | 2023 | 0 | AKH!E4573 |
| AHKFTA | 2024 | 2024 | 0 | AKH!F4573 |
| AHKFTA | 2025 | 2025 | 0 | AKH!G4573 |
| AHKFTA | 2026 | 2026 | 0 | AKH!H4573 |
| AHKFTA | 2027 | 2027 | 0 | AKH!I4573 |
| EVFTA | 2022 | 2022 | 3,1 | EV-NK!D4544 |
| EVFTA | 2023 | 2023 | 2,5 | EV-NK!E4544 |
| EVFTA | 2024 | 2024 | 1,8 | EV-NK!F4544 |
| EVFTA | 2025 | 2025 | 1,2 | EV-NK!G4544 |
| EVFTA | 2026 | 2026 | 0,6 | EV-NK!H4544 |
| EVFTA | 2027 | 2027 | 0 | EV-NK!I4544 |
| UKVFTA | 2022 | 2022 | 3,1 | UKV!D4546 |
| UKVFTA | 2023 | 2023 | 2,5 | UKV!E4546 |
| UKVFTA | 2024 | 2024 | 1,8 | UKV!F4546 |
| UKVFTA | 2025 | 2025 | 1,2 | UKV!G4546 |
| UKVFTA | 2026 | 2026 | 0,6 | UKV!H4546 |
| UKVFTA | 2027 | 2027 | 0 | UKV!I4546 |

| FTA | Period | Year | Source value | Source |
|---|---|---|---|---|
| CPTPP | (I) | 2021 (DERIVED) | 0 | CPTPP!D4544 |
| CPTPP | (II) | 2022 (DERIVED) | 0 | CPTPP!E4544 |
| CPTPP | (III) | 2023 (DERIVED) | 0 | CPTPP!F4544 |
| CPTPP | (IV) | 2024 (DERIVED) | 0 | CPTPP!G4544 |
| CPTPP | (V) | 2025 (DERIVED) | 0 | CPTPP!H4544 |
| CPTPP | (VI) | 2026 (DERIVED) | 0 | CPTPP!I4544 |
| CPTPP | (VII) | 2027 (DERIVED) | 0 | CPTPP!J4544 |
| RCEP A | 2022 | 2022 | 4,5 | RCEPT-A!D4565 |
| RCEP A | 2023 | 2023 | 4 | RCEPT-A!E4565 |
| RCEP A | 2024 | 2024 | 3,5 | RCEPT-A!F4565 |
| RCEP A | 2025 | 2025 | 3 | RCEPT-A!G4565 |
| RCEP A | 2026 | 2026 | 2,5 | RCEPT-A!H4565 |
| RCEP A | 2027 | 2027 | 2 | RCEPT-A!I4565 |
| RCEP B | 2022 | 2022 | 4,5 | B!D4565 |
| RCEP B | 2023 | 2023 | 4 | B!E4565 |
| RCEP B | 2024 | 2024 | 3,5 | B!F4565 |
| RCEP B | 2025 | 2025 | 3 | B!G4565 |
| RCEP B | 2026 | 2026 | 2,5 | B!H4565 |
| RCEP B | 2027 | 2027 | 2 | B!I4565 |
| RCEP C | 2022 | 2022 | 4,5 | C!D4565 |
| RCEP C | 2023 | 2023 | 4 | C!E4565 |
| RCEP C | 2024 | 2024 | 3,5 | C!F4565 |
| RCEP C | 2025 | 2025 | 3 | C!G4565 |
| RCEP C | 2026 | 2026 | 2,5 | C!H4565 |
| RCEP C | 2027 | 2027 | 2 | C!I4565 |
| RCEP D | 2022 | 2022 | 4,5 | D!D4565 |

| FTA | Period | Year | Source value | Source |
|---|---|---|---|---|
| RCEP D | 2023 | 2023 | 4,1 | D!E4565 |
| RCEP D | 2024 | 2024 | 3,6 | D!F4565 |
| RCEP D | 2025 | 2025 | 3,2 | D!G4565 |
| RCEP D | 2026 | 2026 | 2,7 | D!H4565 |
| RCEP D | 2027 | 2027 | 2,3 | D!I4565 |
| RCEP E | 2022 | 2022 | 4,5 | E!D4568 |
| RCEP E | 2023 | 2023 | 4 | E!E4568 |
| RCEP E | 2024 | 2024 | 3,5 | E!F4568 |
| RCEP E | 2025 | 2025 | 3 | E!G4568 |
| RCEP E | 2026 | 2026 | 2,5 | E!H4568 |
| RCEP E | 2027 | 2027 | 2 | E!I4568 |
| RCEP F | 2022 | 2022 | 4,5 | F!D4565 |
| RCEP F | 2023 | 2023 | 4 | F!E4565 |
| RCEP F | 2024 | 2024 | 3,5 | F!F4565 |
| RCEP F | 2025 | 2025 | 3 | F!G4565 |
| RCEP F | 2026 | 2026 | 2,5 | F!H4565 |
| RCEP F | 2027 | 2027 | 2 | F!I4565 |
| VIFTA | 2024 | 2024 | 4,3 | VI!F4207 |
| VIFTA | 2025 | 2025 | 3.6 | VI!G4207 |
| VIFTA | 2026 | 2026 | 2.9 | VI!H4207 |
| VIFTA | 2027 | 2027 | 2.1 | VI!I4207 |

## Advisory & warnings

| Risk code | Level | Risk name | Description | Related data | Legal reference | Recommended action | Verification status |
|---|---|---|---|---|---|---|---|

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| DOC-004 | YELLOW | Other item policy | Item policy (source, Vietnamese): Thuốc chỉ chứa 01 thành phần dược chất XK, NK (09/2024/TT-BYT-DM8) | | 09/2024/TT-BYT-DM | Read the referenced instruments. | Instrument cited in source; validity not verified |
| FTA-013 | YELLOW | FTA rate not lower than MFN | AIFTA 5%: the preferential rate is equal to or higher than the MFN rate (5%) in the source tariff – claiming the FTA brings no saving. | MFN 5% | | Consider the MFN rate (if the origin qualifies for MFN treatment) instead of preparing FTA origin documents. | Not verified – check required |
| HS-003 | YELLOW | Classification Review Required – similar lines exist | Subheading 3004.90 has 28 lines; 3004.90.64 is distinguished from its siblings by: Containing artemisinin other than of subheading 3004.60.10. | 3004.90.10 Transdermal therapeutic system patches for the treatment of cancer or heart diseases; 3004.90.20 Closed sterile water for inhalation, pharmaceutical grade; 3004.90.30 Antiseptics; 3004.90.41 Containing procaine hydrochloride; 3004.90.49 Other; 3004.90.51 Containing acetylsalicylic acid, paracetamol or dipyrone (INN), of a kind taken orally | 31/2022/TT-BTC | Verify the distinguishing features; consider an advance classification ruling if uncertain. | Not verified – check required |
| OR-001 | YELLOW | Country of origin not provided | FTA eligibility cannot be assessed without the country of origin. | | | Enter the country of origin to compare preferential schedules. | Not verified – check required |
| TAX-001 | YELLOW | Several VAT rates | The VAT column shows "5/8/10". | | 181/2025/NĐ-CP | Determine the VAT rate by the nature of goods and reduction rules (174/2025/NĐ-CP, Annex I/II). | Not verified – check required |
| TR-004 | GRAY | Not Assessed – Additional Regulatory Verification Required | The source file records no trade remedy for 3004.90.64. This does NOT mean there is no risk. | | | Check the MOIT Trade Remedies Authority database. | Not verified – check required |
| DQ-001 | GREEN | MFN rate present in the source | The MFN rate 5% for 3004.90.64 was checked against BT2026 (cell BT2026!N4636), basis 26/2023/NĐ-CP. | | 26/2023/NĐ-CP | Verification scope: matched against source file version 2026.04.05; not a substitute for the legal text. | Checked against the source tariff file |

## Item policy

| Item policy |
| --- |
| Thuốc chỉ chứa 01 thành phần dược chất XK, NK (09/2024/TT-BYT-DM8) |

This report is for reference, generated from the source tariff data and advisory rules. It is not a customs decision and does not confirm HS classification, FTA eligibility or legal validity. Users must verify against current legislation.